Home/Pipeline/Not Specified (Neurology Program)

Not Specified (Neurology Program)

Alzheimer's Disease

Clinical-stageActive

Key Facts

Indication

Alzheimer's Disease

Phase

Clinical-stage

Status

Active

Company

Therini Bio

About Therini Bio

Therini Bio is a private, San Francisco-based biotech founded in 2019, advancing a novel therapeutic platform targeting fibrin-mediated neuroinflammation. The company has a clinical-stage pipeline aimed at large markets with high unmet need, such as Alzheimer's disease and diabetic macular edema. It is led by an experienced team with deep expertise in neurology, ophthalmology, and drug development, and is backed by a top-tier syndicate of life science investors.

View full company profile

Therapeutic Areas

Neurology Ophthalmology

Other Alzheimer's Disease Drugs

Drug	Company	Phase	Status
NUZ-001	Neurizon Therapeutics	Preclinical	Active
ALZN002	Alzamend Neuro	Preclinical	Research
P021	Phanes Biotech	Preclinical	Active
PB43D	Phanes Biotech	Preclinical	Active
UB-311	Vaxxinity	Phase 2	Active
Lecanemab	BioArctic	Launched	Active (Commercial)
BAN2401	BioArctic	Preclinical	Active
Undisclosed Programs	johnson-and-johnson-innovative-medicine	Pipeline	Active
MK-6240 (florquinitau)	Lantheus Medical Imaging	Regulatory Filing	Filed
NAV-4694 (flutafuranol)	Lantheus Medical Imaging	Phase 3	Active
LNTH-2620/PI-2620	Lantheus Medical Imaging	Phase 3	Recruiting
itMSCs	Stemedica Cell Technologies	Clinical Development	Active